📊 DARE Key Takeaways
Investment Thesis
Dare Bioscience is in severe financial distress with near-zero revenue (down 99.7% YoY) while burning substantial cash. The company is losing approximately $1.82 for every dollar of revenue and bleeding $11.3M annually from operations, threatening its 2.9 years of cash runway. Despite adequate current liquidity, the lack of revenue generation combined with massive operating losses indicates a pre-commercialization or failed-pipeline biotech company facing existential risk.
DARE Strengths
- Adequate cash position of $23.1M provides runway for operations
- Low leverage with no long-term debt and 0.0x debt-to-equity ratio
- Minimal current liabilities with 1.18x current ratio meeting basic liquidity threshold
DARE Risks
- Revenue collapse of 99.7% YoY indicates failed product commercialization or pipeline failure
- Operating cash burn of $11.3M annually will exhaust cash reserves within 2 years
- Operating margin of -185,378% and net margin of -183,483% demonstrate unsustainable business model
- Negative FCF of -$11.5M with negative ROE of -418% indicates value destruction
- Pharmaceutical R&D company without meaningful revenue suggests products failed FDA approval or market acceptance
Key Metrics to Watch
- Quarterly revenue growth and product pipeline advancement
- Operating cash burn rate and cash runway extension timeline
- Clinical trial results or regulatory approvals for pipeline candidates
DARE Financial Metrics
💡 AI Analyst Insight
Dare Bioscience, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
DARE Profitability Ratios
DARE vs Healthcare Sector
How Dare Bioscience, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
DARE Balance Sheet & Liquidity
DARE 5-Year Financial Trend
5-Year Trend Summary: Dare Bioscience, Inc.'s revenue has declined by 72% over the 5-year period, indicating business contraction. The most recent EPS of $-4.15 indicates the company is currently unprofitable.
DARE Growth Metrics (YoY)
DARE Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.3K | $1.5M | $0.17 |
| Q2 2025 | $4.3K | -$4.0M | $-0.45 |
| Q1 2025 | $9.3K | -$4.4M | $-0.50 |
| Q2 2024 | N/A | $6.2M | $0.72 |
| Q1 2024 | N/A | -$6.8M | $-0.07 |
| Q3 2023 | N/A | $414.0K | $-0.08 |
| Q2 2023 | N/A | $414.0K | $0.00 |
| Q3 2022 | N/A | $414.0K | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DARE Capital Allocation
DARE SEC Filings
Access official SEC EDGAR filings for Dare Bioscience, Inc. (CIK: 0001401914)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DARE
What is the AI rating for DARE?
Dare Bioscience, Inc. (DARE) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are DARE's key strengths?
Adequate cash position of $23.1M provides runway for operations. Low leverage with no long-term debt and 0.0x debt-to-equity ratio.
What are the risks of investing in DARE?
Revenue collapse of 99.7% YoY indicates failed product commercialization or pipeline failure. Operating cash burn of $11.3M annually will exhaust cash reserves within 2 years.
What is DARE's revenue and growth?
Dare Bioscience, Inc. reported revenue of $6.5K.
Does DARE pay dividends?
Dare Bioscience, Inc. does not currently pay dividends.
Where can I find DARE SEC filings?
Official SEC filings for Dare Bioscience, Inc. (CIK: 0001401914) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DARE's EPS?
Dare Bioscience, Inc. has a diluted EPS of $-1.18.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.